Epicrispr Biotechnologies
Overview
Where Epicrispr Biotechnologies is now
Epicrispr Biotechnologies announced a Series C round of $90M on 11 August 2026, led by Octagon Capital and Janus Henderson Investors.
Observed Described in the funding announcement as "provider of a programmable epigenetic medicines platform". Source
Current direction Inferred
What this company is working on
Read from the company's own description of what the funding supports.
Momentum Inferred
AfterRaise Score
- Hiring momentum Open roles and hiring pace
- Market expansion New offices and new countries
- Leadership Executive appointments
- Product activity Launches and releases
Growth timeline
What has happened so far
- 11 August 2026$90M Series CLed by Octagon Capital and Janus Henderson Investors.
Observed The timeline currently holds funding events, because those are the signals AfterRaise observes today. Hiring, leadership, expansion and product events join it with the signals layer.
Moves
Published by the company
No company-published Moves yet
AfterRaise has the funding facts for Epicrispr Biotechnologies from public sources. What it does not have is what the company is doing next, in the company's own words. That part only they can write.
Work here? Publish the first MoveOpportunities
Work this company has opened
No open Opportunities listed
Jobs, projects, partnerships and advisory needs appear here once the company has claimed its room and published them.
Work here? Open the first oneOpen to
Who may approach Epicrispr Biotechnologies
Not yet specified
Epicrispr Biotechnologies has not told AfterRaise which approaches it welcomes. Until it does, we do not assume. Offers to help are held and shown to the company, and the company decides whether to open a conversation.
Work here? Set your preferencesHelpful contributors
People who have contributed here
Nobody yet
When someone offers help and the company says it was useful, they appear here. Reputation on AfterRaise is built from contributions the company confirmed, not from follower counts.
Work here?
This room belongs to Epicrispr Biotechnologies.
Claim it to publish Moves in your own words, open Opportunities, choose who may approach you, and see the offers of help you have received. Everything you publish is reviewed before it appears.
Also moving